Trial Profile
Multicentre, randomized, placebo-controlled, double-blind study of gefitinib plus Fuzheng Kang'ai decoction versus gefitinib in advanced non-small-cell lung cancer patients with EGFR mutation
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 May 2016
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 May 2016 New trial record
- 01 Jan 2015 Study protocol and design of this trial were published in the Trials.